Media ReleasesNyrada

View All Nyrada News


Milestone Achieved in the Nyrada Brain Injury Program


Nyrada Inc (ASX: NYR) provides an update on one of its leading programs for treatment of brain injury.

Nyrada has shown in a preclinical pharmacokinetic study that its lead candidate compounds can cross the blood-brain-barrier (BBB) in the intact uninjured animal brain.

The aim of the Nyrada Brain Injury program is a drug to reduce secondary brain damage following head trauma and stroke in order to improve survivability and patient outcomes. 

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.